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Background: Vagus nerve stimulation has been successfully used as a treatment strat-
egy for epilepsy and affective disorders for years. Transcutaneous vagus nerve stimulation
(tVNS) is a new non-invasive method to stimulate the vagus nerve, which has been shown
to modulate neuronal activity in distinct brain areas. Objectives: Here we report effects of
tVNS on cardiac function from a pilot study, which was conducted to evaluate the feasibility
and safety of tVNS for the treatment of chronic tinnitus.Methods:Twenty-four patients with
chronic tinnitus underwent treatment with tVNS over 3–10 weeks in an open single-armed
pilot study. Safety criteria and practical usability of the neurostimulating device were to
investigate by clinical examination and electrocardiography at baseline and at several visits
during and after tVNS treatment (week 2, 4, 8, 16, and 24). Results:Two adverse cardiac
events (one classified as a severe adverse event) were registered but considered very
unlikely to have been caused by the tVNS device. Retrospective analyses of electrocardio-
graphic parameters revealed a trend toward shortening of the QRS complex after tVNS.
Conclusion: To our knowledge this is one of the first studies investigating feasibility and
safety of tVNS in a clinical sample. In those subjects with no known pre-existing cardiac
pathology, preliminary data do not indicate arrhythmic effects of tVNS.
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INTRODUCTION
Electrical stimulation of the vagus nerve (VNS) is an FDA-
approved therapy tool for both refractory depression and epilepsy
(Schachter and Saper, 1998; Ben-Menachem, 2002; Grimm and
Bajbouj, 2010). Furthermore, it has recently emerged as a promis-
ing therapeutic approach for cardiac diseases (Schwartz et al., 2008;
De Ferrari et al., 2009, 2011). It broadly affects various parts of
the brain including the thalamus, cerebellum, orbitofrontal cor-
tex, limbic system, hypothalamus, and medulla (Chae et al., 2003;
Pardo et al., 2008; Vonck et al., 2008; Kosel et al., 2011). Recently
vagus nerve stimulation paired with auditory stimuli has been
shown to reverse pathological and behavioral changes in an animal
model of tinnitus (Engineer et al., 2011). Traditionally, vagus nerve
stimulation has been performed by the implantation of a neu-
rostimulating device connected to an electrode located along the
cervical branch of the vagus nerve. In order to minimize adverse
effects of this procedure such as coughing during stimulation,
croakiness, general operational and anesthesiological risks, and
high costs, a new non-invasive neurostimulating device has been
developed for transcutaneous stimulation of the afferent auricular
branch of the vagus nerve (ABVN) located medial of the tragus
Abbreviations: AV, atrioventricular; ECG, electrocardiography/
electrocardiographic; LBBB, left bundle branch block; NTS, nucleus of the solitary
tract/nucleus tractus solitarii; tVNS, transcutaneous vagus nerve stimulation; VNS,
conventional vagus nerve stimulation.
at the entry of the acoustic meatus (tVNS®). The tVNS® device
received CE approval in 2010 (CE1275). CE marking is an indica-
tion that a medical device complies with essential health and safety
requirements.
Transcutaneous vagus nerve stimulation (tVNS) targets the
cutaneous receptive field of the ABVN at the outer ear (Ellrich,
2011). The human outer ear is supplied by three sensory nerves,
namely the auriculotemporal nerve, the great auricular nerve, and
the ABVN (Peuker and Filler, 2002). On 14 human ears the com-
plete course of nerve supply was exposed and each branch was
defined by identifying its origin. In all specimens the ABVN was
found to significantly supply the cavity of conchae and exclusively
supply the cymba conchae, which served as stimulation site in the
present study (Peuker and Filler, 2002).
In respect to neuroimaging techniques two functional magnetic
resonance imaging (fMRI) studies have been done investigating
the effect of tVNS applied to the left tragus area in a sample of
four healthy male adults (Dietrich et al., 2008) and to the left
outer ear canal in a sample of 22 healthy volunteers (Kraus et al.,
2007). Stimulation of the earlobe served as control condition. Both
fMRI studies showed blood oxygen level-dependent (BOLD) sig-
nal changes. Earlobe stimulation as a sham control intervention
did not exert similar effects (Kraus et al., 2007). No significant
effects on heart rate, blood pressure, or peripheral microcircula-
tion could be detected during the stimulation procedure (Kraus
et al., 2007). The brain activation pattern under tVNS clearly shares
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features with changes observed during invasive VNS (Chae et al.,
2003; Kraus et al., 2007).
In a pilot study we aimed to assess feasibility and safety of
tVNS in a clinical sample of patients suffering from subjective and
chronic tinnitus.
Since efferent fibers of the vagus nerve modulate cardiac func-
tion, cardiac safety has always been a concern in the therapeutic
use of vagus nerve stimulation (Cristancho et al., 2011). Efferent
vagal fibers to the heart are supposed to be located on the right
side (Nemeroff et al., 2006). In order to avoid cardiac side effects,
electrode placement is performed on the left side in treatment of
central nervous diseases (Nemeroff et al., 2006).
Even if tVNS stimulates selectively afferent vagus nerve fibers, a
potential reflectory effect on efferent vagus nerve function cannot
be excluded. Therefore we performed electrocardiography (ECG)
in all patients at baseline and during tVNS treatment.
MATERIALS AND METHODS
STUDY DESIGN AND SUBJECTS
The present study was conducted as a feasibility and safety study
with an open, single-armed pilot study design. Clinical visits were
planned according to the study protocol at screening, baseline,
week 2, week 4, week 8, week 16, and week 24 (end of treat-
ment) with a further follow-up 4 weeks after termination of the
stimulation in week 28.
The study was approved by the Ethics Committee of the Uni-
versity of Regensburg. All study procedures were conducted in
accordance with the last revision of the Declaration of Helsinki. All
participants gave written informed consent after a comprehensive
explanation of the procedures.
After occurrence of two cardiologic events [one newly diag-
nosed left bundle branch block (LBBB) and one sinusarrhythmic
episode], these two cases were analyzed in detail. Moreover, ECG
data from all patients in the whole sample were retrospectively
analyzed at that time point.
PATIENTS AND RECRUITMENT
The present study included 24 patients [10 male, 14
female; 59.0± 10.7 years (38.4–72.8)] with chronic tinnitus
[167.0± 134.7 months duration (8.1–479.0)]. The trial was reg-
istered in an international database (ClinicalTrials.gov. identifier:
NCT01176734). Patients with moderate to severe tinnitus defined
by a Tinnitus Questionnaire (TQ) score >30 were recruited
between May and August 2010 at the Interdisciplinary Tinnitus
Center of the University of Regensburg. The mean TQ in the study
sample was 49.7± 11.1 (32–75).
Patients with severe internal, neurological, or psychiatric
comorbidities were excluded from the study. Exclusion criteria
were checked by taking a detailed medical history by experi-
enced psychiatrists. Asthma was considered a contraindication
(because of theoretical risk of impairment due to a parasym-
pathetic enhancement by VNS) as well as the permanent use of
left-sided hearing aids and/or tinnitus masking devices.
tVNS NEUROSTIMULATING DEVICE
A tVNS instrument consisting of two titan electrodes mounted
on a gel frame and connected to a wired neurostimulating device
(CM02, Cerbomed, Erlangen, Germany) was used.
The clinical efficacy of VNS requires activation of thick myeli-
nated afferent fibers of the vagus nerve (Vonck et al., 2007). The
fibers of a sensory peripheral nerve such as the ABVN mediate
touch sensation. Consequently, the stimulus intensity of tVNS was
individually adjusted to a level above the individual’s detection
threshold and clearly below the individual’s pain threshold. The
tVNS® device offered a stimulus intensity between 0.1 and 10 mA
with a stimulation frequency of 25 Hz. Stimulation was active for
30 s, followed by a break of 180 s.
In addition, stimulation intensity was applied in an adjustable
way by the patients according to the situational circumstances.
Patients were instructed individually in the usage of the tVNS
device and were recommended to use the stimulator only dur-
ing daytime for safety reasons. They were instructed to adjust
the stimulation intensity in order to achieve a tingling sensation
that should be perceived with no painful percept at all. Every
change in stimulation parameters was logged by the stimulation
device. In 22 of the 24 stimulators, we could compile a detailed
history of stimulation, in the remaining two cases this was not
possible due to technical problems. During the study, patients
used the stimulation device 24.0± 19.3 days with an average of
5.15± 1.80 h a day. The mean intensity of stimulation in the whole
sample was 3.2± 2.5 mA.
ELECTROCARDIOGRAPHY
Twelve-electrode ECGs were recorded with a standard ECG device
(Corina, GE Medical Systems Information Technology Inc., Mil-
waukee, USA) using GE Cardiosoft Software of General Electric
Company, New York, USA. During ECG all patients were laying in
supine position with the tVNS stimulator turned off.
STATISTICAL ANALYSES
All continuous data were displayed as the mean with the standard
deviation and were compared using the paired Student’s t -test or
the two sample Student’s t -test when appropriate. In addition we
reported the effect sizes d for these contrasts to estimate the clinical
significance according to Cohen (d = 0.2 small, 0.5 medium, 0.8
high; Cohen, 1988). Statistical analyses were done in a two-steps-
approach for the whole sample and for the sample without the two
patients with adverse events. Statistical significance was assumed
for a p-value< 0.05.
RESULTS
After occurrence of two cardiac events (one newly diagnosed LBBB
and one sinusarrhythmic episode) the two cases were analyzed in
detail. In addition, we conducted an analysis of all ECG recordings
performed during the course of the study up to this time point as
an interim analysis, in order to address safety issues.
For the whole sample missing values for visit 2 (55%) and
3 (82%) were high; thus, we concentrated on contrasts between
screening/baseline (5%= 1 value missing for QRS), visit 1 (14%
missing), and last available visit (32% missing). In two patients
cardiac adverse events during tVNS had occurred.
A 62 years old female (patient 1) developed a palpitation
episode that was monitored and treated in an intensive care unit.
This event was therefore classified as a severe adverse event and
reported immediately to the sponsor and the local ethics com-
mittee. The patient had noticed palpitation on a hot Saturday in
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FIGURE 1 | ECG of patient 2 at baseline, week 2 and week 4 visit.
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FIGURE 2 | ECG displaying LBBB at week 8 visit (patient 2).
the summer of 2010 that worsened in the course of the day and
led to consultation of a physician in the evening. She was initially
supplied with Calcium and Magnesium formula but when the
complaints persisted even on the following day she sought help in
a hospital and was initially observed in an intensive care unit after
administration of nitroglycerine inhaler. After normal results were
obtained at echocardiography, duplex sonography of the carotids,
24 h ECG monitoring, and thoracal X-ray she was dismissed from
hospital without complaints 1 day later. Elevation of the dosage
of her beta-blocking antiarrhythmic drug from 2.5 mg b.i.d. to
5 mg b.i.d. was recommended. Further exploration revealed that
the patient had suffered comparable events earlier in the past but
in-patient-treatment had not been necessary so far. tVNS treat-
ment had been stopped immediately in this patient and she was
retracted from the study.
A 67 year-old male patient (patient 2) displayed a LBBB with
atrioventricular conduction time of 160 ms in a routine echocar-
diographic control performed after 8 weeks of tVNS, which
had not been there at baseline and at the prior visits (screen-
ing/baseline, week 2, week 4). Prior echocardiography had not
revealed any pathological results as shown in Figure 1. The patient
himself did not experience any symptoms, the LBBB was detected
in a routine control ECG according to the study protocol (see
Figure 2). For improvement of mood and sleep he was on medica-
tion with mirtazapine (15 mg/day) and pre-existing arterial hyper-
tension was treated with metoprolol 200 mg/day. Additional car-
diac risk factors included smoking (10–15 cigarettes/day for almost
50 years), obesity (180 cm, 100 kg; BMI= 30.9 kg/m2), and hyper-
lipidemia. Extensive internal check-up including several ECG and
sonographic examinations revealed a concentric hypertrophy of
the left ventricle without regional cardiac movement disorders.
Heart catheter examinations were recommended but refused by
the patient. The LBBB was completely reversible, further ECG
controls did not show similar episodes so far (see Figure 3). tVNS
stimulation was immediately stopped after detecting the LBBB at
week 8 study visit. This event was not classified as a severe adverse
event as it did not lead to hospitalization of the patient or other
grave impairment.
Further reported adverse events included headache (3×),
breathing difficulties (3×), chest sensation (3×), dizziness (2×),
subjective hearing impairment (2×), worsening of tinnitus, neck
pain, croakiness, and sleeping disorder. Notably, all these com-
plaints were reported to have been perceived transiently, they could
not be objectified and no specific actions were taken. For none of
these side effects there was a clear hint for a causal relationship to
the intervention itself.
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FIGURE 3 | ECG at follow-up 6 weeks after LBBB (patient 2).
Side effects clearly related to the intervention were tech-
nical problems [contact problems (4×)] and local problems
[local electrode pressure (11×); pain at stimulation with high
intensity (3×)].
Statistical analyses were performed on various ECG parame-
ters [heart beats per minute, PQ interval (ms), QRS complex
(ms), and QTc (ms)] both for the whole sample (n= 24) and
the sample without the two patients with adverse events (n= 22;
see Figure 4). For the whole sample none of the analyzed parame-
ters showed significant differences between the three time points,
effect sizes were small (all ps> 0.246; all ds< 0.312). When the
two patients with cardiac averse events were excluded from analy-
sis, a significant reduction of the QRS complex with a medium
effect size (p= 0.047; d = 0.541) from screening to the termina-
tion emerged; all other contrasts were not significant with small
effect sizes (all ps> 0.382; all ds< 0.206). All results are displayed
in detail in Figure 4.
DISCUSSION
The purpose of this pilot study was to evaluate the feasibility
and safety of tVNS in the treatment of chronic tinnitus. This
is one of the first studies investigating feasibility and safety of
tVNS in a clinical sample (Stefan et al., 2012). The main findings
of our study were that (1) tVNS is feasible in tinnitus patients
without any signs of long-term worsening of tinnitus complaints
and that (2) in those patients without a history of known car-
diac disease, these data suggest that tVNS cannot be considered
unsafe. It was well tolerated in the majority of patients of this
study sample. (3) With respect to the measured cardiac parame-
ters, the study showed that tVNS of the left ABVN is unlikely to
cause adverse cardiac reactions. In both of the reported cardiac
adverse events other explanations for the symptoms were exist-
ing in the patients. Patient 1 had experienced sinusarrhythmic
episodes already in the past, in patient 2 the comorbid condition
of hypertension had caused concentric cardiac hypertrophy which
might have contributed to the described temporary LBBB. In the
statistical analysis of the whole sample no effects on ECG parame-
ters were observed, after exclusion of the patients with side effects
there was a significant reduction of the QRS time. However, this
effect is small, and significance would not have survived correction
for multiple testing. Thus it remains to be elucidated by further
studies whether tVNS reduces the QRS time or whether the QRS
time remains unaffected by tVNS. Definitively our data do not
provide a hint for a prolongation of the QRS complex which is
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FIGURE 4 | Cardiac parameters during tVNS stimulation for both the whole sample and the sample without the 2 patients experiencing adverse
cardiac events.
a known predictor of cardiac morbidity and mortality (Shamim
et al., 1999; Kashani and Barold, 2005; Brenyo and Zareba, 2011).
The authors are well aware of the preliminary character of the
presented data as the study was originally not designed for the
assessment of cardiac effects of left-sided tVNS, but was rather
conducted to examine feasibility and efficacy of tVNS in a sample
of tinnitus patients. Therefore, the analyzed ECG recordings were
performed based on standard safety considerations. Stable somatic
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comorbidities including cardiac diseases were not considered as
a contraindication for participation in the study, unfortunately
complicating the interpretation of the presented data ex post.
Nonetheless, we would recommend a more conservative selection
of patients in future clinical studies.
This is in line with the low incidence of adverse cardiac reactions
during the long-term experience in more than 50,000 patients
with implanted left VNS for treatment of epilepsy and depression
(Ben-Menachem, 2002; Cristancho et al., 2011).
After intensive workup the two described cardiac adverse events
during the study are more probably due to individual pre-existing
cardiac risk factors such as known sinus-arrhythmias (patient 1),
hypertensive state, and the attributable dilatative cardiomyopathy
(patient 2).
Taking into consideration the relatively high age of our sample,
the risk of internal somatic comorbidities is much higher than in
general population samples and one should not prematurely judge
the tVNS to be causally related to the adverse cardiac reactions
described above.
Thus, our preliminary data do not provide concrete hints
for relevant influences of tVNS on cardiac rhythm. In our
opinion tVNS as approved by CE marking represents an inno-
vative and promising new approach in non-invasive modu-
lation of brain activity that might exert benefits in a vari-
ety of neuropsychiatric disorders and merits further research.
Nevertheless, in light of the potential of tVNS to modulate
conduction system of the heart, ECG recordings are recom-
mended in every study of tVNS in order to obtain further
safety data.
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